- Details
- The 2021 ASCO GU Cancers Symposium provided many updates and developments in the field of kidney cancer. Joining Alicia Morgans, MD, MPH, is Wenxin Xu, MD, offering context to the data and the clinical implications. Dr. Xu and Dr. Morgans review the details of the CLEAR study examining first-line lenvatinib and everolimus or lenvatinib and pembrolizumab versus sunitinib in patients with advanced r...
|
- Details
- Immune checkpoint blockade is a first line therapeutic option in either platinum ineligible patients or carboplatin eligible patients whose tumors also express PD-L1. Patients who are ineligible for cisplatin and progress on immune checkpoint blockade have limited treatment options, and many efforts are underway to expand the therapeutic armamentarium for this disease context. In this conversation...
|
- Details
- Platinum-based cytotoxic chemotherapy has been the standard of care for patients with advanced urothelial carcinoma based on improved survival compared to placebo. However, objective response rates are at best 50% and median overall survival is relatively poor at less than 18 months. This has driven the rationale for additional approaches. In first-line (1L) therapy for patients who are not cispla...
|
- Details
- As we try to decrease the burden that bladder cancer patients face, the topic of deintensification of the management of low-risk, non-muscle-invasive bladder cancer has become more and more popular. The 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a session titled, Optimizing Personalized Management of Nonmuscle-Invasive Bladder Cancer. Angela Smith...
|
- Details
- Petros Grivas, MD, PhD and Andrea Apolo, MD highlight results from a pooled analysis of a landmark phase I dose-escalation study and 7 subsequent expansion cohorts. In this study combinations of cabozantinib and nivolumab (CaboNivo) and cabozantinib, nivolumab, and ipilimumab (CaboNivoIpi) demonstrated promising efficacy and safety in a dose-escalation phase I study among patients with metastatic...
|
- Details
- In January 2020, pembrolizumab was approved for the treatment of patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected to not undergo cystectomy. In this conversation, Arjun Balar, MD, and Petros Grivas, MD, Ph.D. discuss the use of pembrolizumab in the real-world sett...
|
- Details
- The SWOG 1500 trial is a randomized phase II trial and studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of tumor cells by blocki...
|
- Details
- Adjuvant nivolumab could provide a treatment option for patients with muscle-invasive urothelial carcinoma to reduce the risk of recurrent cancers and death, the CheckMate 274 study finds. The standard-of-care treatment for muscle-invasive urothelial carcinoma is cisplatin-based neoadjuvant therapy followed by radical surgery. However, many patients are cisplatin-ineligible. CheckMate274 is a phas...
|
- Details
- Urothelial carcinomas of the upper urinary tract (UTUCs) are rare, with poorer stage-for-stage prognosis than urothelial carcinomas of the urinary bladder. No international consensus exists on the benefit of adjuvant chemotherapy for patients with UTUCs after nephroureterectomy with curative intent. The POUT (Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer) trial a...
|
- Details
- In this conversation Toni Choueiri, MD, and Sumanta Kumar Pal, MD join Petros Grivas, MD, PhD reviewing the evolving landscape of metastatic renal cell carcinoma and highlight the trial design and the recently published CLEAR study. CLEAR is a phase 3 trial, that recruited patients with advanced renal cell carcinoma who had not received prior systemic therapy evaluating lenvatinib plus pembrolizum...
|
